Short description
IM Therapeutics develops personalized immuno-therapeutic drugs.
Description
IM Therapeutics develops personalized immunotherapeutic drugs for autoimmune diseases based on the genetic risk attributed by human leukocyte antigen (HLA) genes. Their lead candidate drug is an oral drug that starves the autoimmune process in type 1 diabetes (T1D) by blocking DQ8 on specific immune cells. Their goal is to preserve pancreatic beta-cell function and maintain normal insulin production in at-risk and early-stage patients with type 1 diabetes. They are leveraging Their HLA platform to expand their pipeline beyond T1D, to include drug development for Celiac disease (gluten sensitivity) as well as potential additional autoimmune diseases.
It was founded in 2015 and is headquartered in Aurora, Colorado.
Last funding
Nopepepe
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Aurora, Colorado, United States, North America
Founded on
January 1, 2015
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$56378 - 90123
Sign in for full access
Investors
Noway Youcantaccess, Uh Ohhhh, Cannot Access
Sign in for full access
Founders
Aaron Michels, Peter Gottlieb